A recent study reported in the journal Clinical Cancer Research, metronomic administration of Topotecan and pazopanib showed a statistically significant antitumor activity compared to respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors. In vitro, Topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not. In vivo, combination of Topotecan + Pazopanib (TP+PZ) demonstrated significant anti-tumor activity and significant enhancement in survival compared to the respective single agents in all models. Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction. News link: http://www.sciclips.com/sciclips/drug-discove...